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| INTRODUCTION
Patients with an acute medical illness have an increased risk of venous thromboembolism (VTE) during hospitalization that persists following discharge.
1,2 Several randomized trials have demonstrated the efficacy of VTE prophylaxis with direct oral anticoagulants (DOACs) compared to low-molecular-weight heparin for 6 to 14 days. [3] [4] [5] Based on the results of the APEX trial, the US Food and Drug
Administration has licensed betrixaban for first-line thromboprophylaxis in acute medically ill patients at high risk for VTE. The identification of these high-risk patients may be determined clinically or by use of risk assessment models (RAMs) that rely on integer-based scoring systems of known risk factors. 6, 7 Padua and
IMPROVE (International Medical Prevention Registry on Venous
Thromboembolism) are 2 validated scores for risk stratification of acute medically ill patients. [8] [9] [10] These RAMs demonstrated modest performance in validation data sets. [11] [12] [13] Machine learning algorithms are constructed to search for patterns in data that provide maximum predictive ability. 14, 15 These learning methods have demonstrated superiority to traditional diagnostic and prognostic tools in various domains. [16] [17] [18] [19] However, the performance of machine learning methods in the prediction of the occurrence of VTE has not been previously explored. The aim of this study is to develop and evaluate the performance of machine learning in the prediction of VTE through 77 days among hospitalized acutely medically ill patients enrolled in the APEX (Acute Medically
Ill VTE Prevention With Extended Duration Betrixaban) trial.
| METHODS

| Source of data
The APEX trial has been described previously. 20 In brief, APEX was a randomized, double-blind, double-dummy, active-controlled phase 3 clinical trial that enrolled 7513 patients hospitalized for a specific acute medical illnesses (heart failure, respiratory failure, infectious disease, rheumatic disease, or ischemic stroke). Patients had reduced mobility and specific risk factors for VTE (aged ≥75 years, baseline D-dimer ≥2× upper the limit of normal, or 2 additional ancillary risk factors for VTE). Patients were randomized in a 1:1 ratio to receive 80 mg of oral betrixaban for 35 to 42 days, or 40 mg of subcutaneous enoxaparin for a standard duration of 6 to 14 days. Patients were followed for up to 77 days. The 6454 subjects (86%) that had compression ultrasound (CUS) assessment for asymptomatic DVT were included in the data set.
| Outcome
The primary outcome was a composite of asymptomatic and symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), and VTErelated mortality through the end of study (77 days). Asymptomatic DVT was assessed by CUS from 32 to 47 days after hospitalization. An independent, blinded, centralized, end-point adjudication committee assessed symptomatic and ultrasound end points.
| Predictive models
Ensemble learning is a type of machine learning that combines predictions across different candidate models. A total of 39 candidate machine learning algorithms in 5 families of models were built using 10-fold cross validation. Broadly, the families of candidate models built included generalized additive models, elastic net (penalized logistic regression), extreme gradient boosting, random forests, a Bayesian logistic regression with default priors, and a simple classification tree. The super learner ensemble method then used cross validation to select weights that were applied to each candidate model to combine predictions. The weights that the super learner model assigned to each model are demonstrated in Tables S2 and S3 . The first model (ML) was built with a total of 68 variables, which comprised all the baseline variables available in the APEX trial data set that had <1% missing data. A second "reduced' model (rML) was developed using 16 variables that were thought, a priori, to be risk factors for VTE. These 16 variables were either part of the IMPROVE and/or Padua scores or were identified in a literature search to have associations with VTE. Both super learner ensemble models were compared to each other and to the IMPROVE risk score. The variables included in each of the models are summarized in the Table S1 . 
| Risk stratification
The distribution of the predicted risks produced by rML model was plotted and divided into tertiles. Patient characteristics and outcome event rates were described, and median predicted risks were reported in each tertile. Odds ratios and 95% confidence intervals were computed comparing the observed rate of VTE across the
tertiles. An implementation of the rML model in 3 different patient profiles was summarized and marked in relation to the risk distribution in the APEX trial.
Analyses were conducted by an academic research organization,
Percutaneous-Pharmacologic Endoluminal Revascularization for
Unstable Syndromes Evaluation. All authors drafted and critically revised the manuscript and took responsibility for its content. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
| RESULTS
| Baseline characteristics
Baseline characteristics and outcome summary of the patients enrolled in the APEX trial are shown in Table 1 . The mean age was 76 years; 46.1% of patients were hospitalized for heart failure, 11.6%
for respiratory failure, 11.2% for ischemic stroke, 27.9% for acute infection, and 3.1% for rheumatic disease. A total of 405 patients Hormone replacement, n (%) 59 (0.9) 53 (0.9) 6 (1.5) .43
TA B L E 1 Baseline characteristics
Inherited or acquired thrombophilia (%)
BMI, body mass index; IQR, interquartile; P-gp, P-glycoprotein; SD, standard deviation; VTE, venous thromboembolism.
(6.3%) had a VTE through the end of the study. Approximately 76% of VTEs were asymptomatic DVT, 9.6% were symptomatic DVT, 7.1% were PE, and 10% were VTE-related deaths.
| Performance measures
The ML model had a c-statistic of 0.69 and the rML model had a c-statistic of 0.68, with both demonstrating superior discriminative ability in this data set compared to the IMPROVE score, which had a c-statistic of 0.59 (P < .001). The 2 super learner models had similar discrimination, with a P value of .28 ( Figure 1A ).
The super learner models appear well calibrated compared to the IMPROVE score, as shown in the calibration plot ( Figure 1B ). Both the ML and rML models demonstrated good calibration using the Hosmer-Lemeshow test (P = .06 and P = .44, respectively). In contrast, the IMPROVE score demonstrated poor calibration (HosmerLemeshow, P < .001).
F I G U R E 1
Receiver operator characteristics curve and calibration plot. A, the receiver operator characteristics curve for the composite VTE outcome for the complete super learner ensemble (ML), the reduced super learner ensemble (rML), and the IMPROVE risk score. B, the calibration plot for the composite VTE outcome for the complete super learner ensemble (ML), the reduced super learner ensemble (rML), and the IMPROVE risk score. VTE, venous thromboembolism 
| Risk stratification
The frequency of the predicted risks produced by the reduced super learner model (rML) was plotted in Figure 2 and color-coded according to tertiles of risk. Predicted risks were estimated by refitting the rML model to the full data set, with the modification that every patient was assumed to receive the betrixaban treatment. This was done to ensure that the risk stratification is due to additional covariate information, separate from the treatment effects demonstrated in the APEX trial.
Patient characteristics and outcomes in each tertile are described in Table 2 . The lowest tertile included predicted risks between 0 and ≤3.3%, with a median risk of 2.7%. The second tertile represented intermediate risks ranging from >3.3%-<5%, with a median of 5%. The third tertile predicted risks ≥5%, with a median of 7.4%. The observed VTE rates in the tertiles were 2.5% in the lowest tertile, 4.8% in the middle tertile, and 11.4% in the third tertile. The odds of VTE in the second and third tertiles, compared to the lowest tertile, were 1.97 and 5.04, respectively. Table 3 shows VTE prediction risk estimates obtained from the rML model algorithms for 3 different acutely ill patient profiles, and Figure 3 marks these patients' risk of VTE on a plot of the distribution of risks in the APEX trial. Embolism Risk) trial presents a cautionary tale. In APEX, the IMPROVE score did not discriminate on outcomes with a similar score in those that did and did not have a VTE. Similarly, using an integer-based score in the MARINER trial underestimated the event rate.
| DISCUSSION
21
However, traditional risk scores offer the advantage of ease of use and simple computation by the physician at the point of care, which previously would have outweighed performance limitations. The IMPROVE score and the dual antiplatelet therapy (DAPT) score have a mobile application that has been downloaded over 100 000 times. [22] [23] [24] Similarly, ML models may be implemented on mobile platforms that would optimize both the computational and convenience challenges that previously necessitated using oversimplified integer-based models. BMI, body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; NYHA, New York Heart Association; VTE, venous thromboembolism.
TA B L E 3 Venous thromboembolism risk prediction using the reduced machine learning (rML) model in 3 different patient profiles
The super learner ensemble algorithm provides advantages of allowing a priori specification of an algorithm that combines estimates from traditional regression models and machine learning algorithms and determines the weights to apply to each model. 25 This allows the data to "decide" the weights to apply to each method in order to achieve the best fit rather than arbitrarily choosing an approach that may not necessarily provide the best performance.
Our reduced model demonstrated similar discrimation compared to the complete model and qualitatively appeared more highly calibrated with patient outcomes through a wider range of risks and had a high P value for the Hosmer-Lemeshow test. This finding corroborates a previous study, which used "untransformed" and "reduced"
super learner algorithms for the prediction of mortality in intensive care unit patients in which the reduced model performed similarly to the untransformed model. 
| Limitations
Machine learning methods are often described as "black box," as they do not provide information on the directionality or magnitude of effect for variables on the outcome. 
| CONCLUSION
This analysis is the first to evaluate the performance of machine learning algorithms, built on randomized clinical trial data, for the prediction of VTE among acute medically ill patients. The super learner produced the highest c-statistic for prediction of VTE compared to the IMPROVE score and produced risk estimates that were well calibrated with observed outcomes. Patients in the lowest tertiles of risk had the lowest observed outcomes, while those in the highest tertile had the highest rate of VTE that corresponds to approximately 5-fold increased odds of VTE compared to the lowest tertile. Therefore, the rML model can be used to identify and group patients according to risk in a clinically meaningful way.
Further research is needed to evaluate the effect of the use of this algorithm on outcomes in a clinical setting.
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